Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR104 and Sorafenib in Advanced Hepatocellular Carcinoma
NCT00862082Phase 2Terminated
- Sponsor
- Proacta Inc.
- Start
- Mar 2009
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of PR-104 in hepatocellular carcinoma (HCC), sponsored by Proacta Inc.. Started Mar 2009; status: terminated.
02
Drugs
PR-104
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00862082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862082.